# Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study

Study · id `cardio:ct-nct05639010` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05639010](<https://clinicaltrials.gov/study/NCT05639010>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05639010

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 410 participants.

## Technical summary

Registry record NCT05639010. Randomized; no masking; primary purpose treatment. Start 2023-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 410 participants (planned count; ClinicalTrials.gov record NCT05639010, source copy `cardio:ctgov-nct05639010-2026-03-23`, retrieved 2026-10-26)
- Started: 2023-01-01 (actual) (ClinicalTrials.gov record NCT05639010, source copy `cardio:ctgov-nct05639010-2026-03-23`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05639010, source copy `cardio:ctgov-nct05639010-2026-03-23`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05639010, source copy `cardio:ctgov-nct05639010-2026-03-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05639010, source copy `cardio:ctgov-nct05639010-2026-03-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05639010-2026-03-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study
- Condition: End Stage Renal Disease
- Intervention (Device): regular hemodialysis
- Intervention (Device): hemoperfusion combined with hemodialysis
- Lead sponsor: Changhai Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Changhai Hospital (`cardio:org-changhai-hospital`)

## Provenance

Content hash: 5cbde0282c9f2e2834616ac9eda821947c0d189d0a763500f71ec317e31d5562
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
